Peripheral nerve transfers change target muscle structure and function
Artikel i vetenskaplig tidskrift, 2019
Selective nerve transfers surgically rewire motor neurons and are used in extremity reconstruction to restore muscle function or to facilitate intuitive prosthetic control. We investigated the neurophysiological effects of rewiring motor axons originating from spinal motor neuron pools into target muscles with lower innervation ratio in a rat model. Following reinnervation, the target muscle's force regenerated almost completely, with the motor unit population increasing to 116% in functional and 172% in histological assessments with subsequently smaller muscle units. Muscle fiber type populations transformed into the donor nerve's original muscles. We thus demonstrate that axons of alternative spinal origin can hyper-reinnervate target muscles without loss of muscle force regeneration, but with a donor-specific shift in muscle fiber type. These results explain the excellent clinical outcomes following nerve transfers in neuromuscular reconstruction. They indicate that reinnervated muscles can provide an accurate bioscreen to display neural information of lost body parts for high-fidelity prosthetic control.
Författare
Konstantin D Bergmeister
Medizinische Universität Wien
Martin Aman
Medizinische Universität Wien
Silvia Muceli
Universitätsmedizin Göttingen
Imperial College London
Ivan Vujaklija
Imperial College London
Krisztina Manzano-Szalai
Medizinische Universität Wien
Ewald Unger
Medizinische Universität Wien
Ruth A. Byrne
Medizinische Universität Wien
Clemens Scheinecker
Medizinische Universität Wien
Otto Riedl
Medizinische Universität Wien
Stefan Salminger
Medizinische Universität Wien
Florian Frommlet
Medizinische Universität Wien
Gregory H. Borschel
Hospital for Sick Children University of Toronto
Dario Farina
Imperial College London
Oskar C. Aszmann
Medizinische Universität Wien
Science advances
2375-2548 (eISSN)
Vol. 5 1 eaau2956Ämneskategorier
Medicinska grundvetenskaper
Klinisk medicin
Medicinsk bioteknologi
DOI
10.1126/sciadv.aau2956